10 papers
Meta-Analysis of High-Dimensional Surrogate Markers
Arthur Hughes, Rodolphe Thiébaut, Layla Parast +1
When direct measurement of a clinically relevant primary endpoint in a clinical trial is infeasible, a surrogate endpoint may be used instead to infer treatment effects. Trial-leve…
A Functional-Class Meta-Analytic Framework for Quantifying Surrogate Resilience
Emily Hsiao, Layla Parast
A surrogate marker is a biomarker or other physical measurement used to replace a primary outcome in clinical trials to evaluate a treatment effect when the primary outcome of inte…
A Causal Framework for Evaluating Jointly Longitudinal Outcomes and Surrogate Markers: A State-Space Approach
Silvaneo V. dos Santos, Layla Parast
Surrogate markers offer the potential to reduce the burden of data collection by replacing costly or invasive primary outcomes with more accessible measurements, provided that they…
Correcting for Missing Data When Evaluating Surrogate Markers in a Clinical Trial
Sarah C. Lotspeich, P. D. Anh. Nguyen, Layla Parast
Evaluating treatment effects is critical in clinical trials but sometimes involves lengthy, invasive, or costly follow-up procedures. In these cases, surrogate markers, which provi…
A Bayesian Critique of Rank-Based Methods for Surrogate Marker Evaluation
Pietro Carlotti, Layla Parast
Surrogate markers are often employed in clinical trials to replace primary outcomes that may be difficult, expensive, or time-consuming to measure directly. These markers can accel…
Resilience Measures for the Surrogate Paradox
Emily Hsiao, Lu Tian, Layla Parast
Surrogate markers are often used in clinical trials to evaluate treatment effects when primary outcomes are costly, invasive, or take a long time to observe. However, reliance on s…